China Biotech Firms Race to Develop Cancer Vaccines After Moderna Breakthrough
SCMP · 1 SOURCESabout 2 hours ago2 MIN
Summary
A wave of excitement has swept through China's biotechnology sector following the announcement by Moderna and Merck that their personalized mRNA cancer vaccine successfully reduced the risk of melanoma returning or spreading in patients. The phase three trial involved approximately 1,140 patients and marked a historic first for mRNA cancer vaccine technology. Hong Kong-listed companies are now racing to advance their own programmes in what analysts describe as a rapidly expanding market.
Key Points
- Jiangsu Hengrui Pharmaceuticals and CK Life Sciences, the latter backed by tycoon Li Ka-shing, are among the companies with cancer vaccines in development .
- Jefferies reports China has already built a pipeline of more than 100 cancer vaccine programmes, positioning the country as a major player in the field .
- Shanghai-based Everest Medicines saw its Hong Kong-listed shares climb 34 percent over the past five days following the Moderna news .
- CK Life Sciences, a unit of Li Ka-shing's CK Group, experienced a stock jump exceeding 11 percent during the same period .
- Nearly 2.6 million people die from cancer in China annually, creating a massive potential market for effective therapeutic vaccines .
Why It Matters
The race to develop cancer vaccines represents a pivotal shift in oncology treatment, with China's large pipeline potentially offering new hope for millions of patients. While the initial breakthrough focuses on melanoma, analysts warn that replicating this success across other tumour types and achieving cost-effective manufacturing at scale remain significant hurdles .
The race to develop cancer vaccines represents a pivotal shift in oncology treatment, with China's large pipeline potentially offering new hope for millions of patients. While the initial breakthrough focuses on melanoma, analysts warn that replicating this success across other tumour types and achieving cost-effective manufacturing at scale remain significant hurdles .